Related Experiment Video
Updated: Dec 10, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeted Therapies in Early Stage NSCLC: Hype or Hope?
Alex Friedlaender1, Alfredo Addeo1, Alessandro Russo2
1Oncology Department, University Hospital of Geneva, 1205 Genève, Switzerland.
Abstract:
Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC.
Insights
Targeted therapies are transforming non-small-cell lung cancer (NSCLC) treatment. This review explores novel targeted options for early-stage NSCLC, aiming to improve survival rates beyond surgery and chemotherapy.
Area of Science:
- Oncology
- Medical Research
Background:
- Non-small-cell lung cancer (NSCLC) accounts for 85% of lung cancers globally, with increasing incidence.
- While treatments have improved for advanced NSCLC, early-stage disease survival post-surgery remains suboptimal, with high relapse rates after adjuvant chemotherapy.
Purpose of the Study:
- To review the current landscape of targeted therapeutic options for early-stage non-small-cell lung cancer.
- To discuss advancements in molecularly-oriented studies and novel agents for early NSCLC.
Main Methods:
- Literature review of targeted therapies in early-stage NSCLC.
- Analysis of molecularly-oriented studies and predictive biomarkers.
Main Results:
- Targeted therapies have shown promise in the metastatic setting, driven by oncogenic drivers.
- Previous trials of targeted therapies in unselected early-stage NSCLC patients did not show survival benefits.
- Identification of predictive biomarkers and development of novel agents are paving the way for new treatment strategies.
Conclusions:
- There is a significant need for improved treatments in early-stage NSCLC due to disappointing survival rates after resection and adjuvant chemotherapy.
- The development of targeted therapies, guided by predictive biomarkers, represents a promising new era for managing early-stage NSCLC.
- This review highlights the evolving therapeutic algorithm for early NSCLC, focusing on molecularly-driven approaches.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy